JP2016521539A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521539A5 JP2016521539A5 JP2015558676A JP2015558676A JP2016521539A5 JP 2016521539 A5 JP2016521539 A5 JP 2016521539A5 JP 2015558676 A JP2015558676 A JP 2015558676A JP 2015558676 A JP2015558676 A JP 2015558676A JP 2016521539 A5 JP2016521539 A5 JP 2016521539A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- particle
- antigen
- malaria
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 241001502567 Chikungunya virus Species 0.000 claims description 7
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 7
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 53
- 201000004792 malaria Diseases 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 16
- 101710091045 Envelope protein Proteins 0.000 claims 13
- 101710188315 Protein X Proteins 0.000 claims 13
- 102100021696 Syncytin-1 Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 230000003612 virological effect Effects 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 241000700605 Viruses Species 0.000 claims 8
- 229960005486 vaccine Drugs 0.000 claims 8
- 210000000234 capsid Anatomy 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 241000710929 Alphavirus Species 0.000 claims 3
- 201000009182 Chikungunya Diseases 0.000 claims 3
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 claims 3
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 claims 3
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 241000710946 Barmah Forest virus Species 0.000 claims 2
- 241000710831 Flavivirus Species 0.000 claims 2
- 241000710951 Western equine encephalitis virus Species 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000003046 sporozoite Anatomy 0.000 claims 2
- 230000002463 transducing effect Effects 0.000 claims 2
- 241000972773 Aulopiformes Species 0.000 claims 1
- 241000178568 Aura virus Species 0.000 claims 1
- 241000231314 Babanki virus Species 0.000 claims 1
- 241000868138 Cabassou virus Species 0.000 claims 1
- 108090000565 Capsid Proteins Proteins 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 108010041986 DNA Vaccines Proteins 0.000 claims 1
- 229940021995 DNA vaccine Drugs 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims 1
- 241000353621 Eilat virus Species 0.000 claims 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims 1
- 241000465885 Everglades virus Species 0.000 claims 1
- 241000231322 Fort Morgan virus Species 0.000 claims 1
- 241000710948 Highlands J virus Species 0.000 claims 1
- 241000231318 Kyzylagach virus Species 0.000 claims 1
- 241000608292 Mayaro virus Species 0.000 claims 1
- 241000763097 Me Tri virus Species 0.000 claims 1
- 241000710949 Middelburg virus Species 0.000 claims 1
- 241000465889 Mosso das Pedras virus Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000328499 Rio Negro virus Species 0.000 claims 1
- 241000710942 Ross River virus Species 0.000 claims 1
- 241001660014 Salmon pancreas disease virus Species 0.000 claims 1
- 241000710961 Semliki Forest virus Species 0.000 claims 1
- 241000710960 Sindbis virus Species 0.000 claims 1
- 241001472492 Southern elephant seal virus Species 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 241000868137 Tonate virus Species 0.000 claims 1
- 241000951300 Trocara virus Species 0.000 claims 1
- 241000608278 Una virus Species 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000010382 chemical cross-linking Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 235000019515 salmon Nutrition 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361830436P | 2013-06-03 | 2013-06-03 | |
| US61/830,436 | 2013-06-03 | ||
| US201361906583P | 2013-11-20 | 2013-11-20 | |
| US61/906,583 | 2013-11-20 | ||
| PCT/JP2014/065166 WO2014196648A1 (en) | 2013-06-03 | 2014-06-02 | Malaria vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521539A JP2016521539A (ja) | 2016-07-25 |
| JP2016521539A5 true JP2016521539A5 (cg-RX-API-DMAC7.html) | 2017-07-06 |
| JP6734651B2 JP6734651B2 (ja) | 2020-08-05 |
Family
ID=52005658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558676A Active JP6734651B2 (ja) | 2013-06-03 | 2014-06-02 | マラリアワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9512190B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3004348B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6734651B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102494564B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105431535A (cg-RX-API-DMAC7.html) |
| AP (1) | AP2015008926A0 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014275772B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015030229B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2913832C (cg-RX-API-DMAC7.html) |
| IL (1) | IL242656B (cg-RX-API-DMAC7.html) |
| MX (1) | MX386234B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2702163C2 (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201709917VA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI687442B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014196648A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201508642B (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013221187B9 (en) | 2012-02-16 | 2018-01-04 | Vlp Therapeutics, Inc. | Virus like particle composition |
| TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| WO2016021209A1 (en) | 2014-08-08 | 2016-02-11 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein e3 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| EP3191589B1 (en) | 2014-09-11 | 2025-11-26 | VLP Therapeutics, Inc. | Flavivirus virus like particle |
| US10166281B2 (en) * | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| US9968665B2 (en) * | 2015-09-16 | 2018-05-15 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| SG11201909265QA (en) | 2017-04-19 | 2019-11-28 | Inst Res Biomedicine | Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to |
| CN110612116A (zh) | 2017-05-08 | 2019-12-24 | 磨石肿瘤生物技术公司 | 甲病毒新抗原载体 |
| KR102823029B1 (ko) | 2017-12-20 | 2025-06-20 | 브이엘피 테라퓨틱스 인코포레이티드 | 알파바이러스 레플리콘 입자 |
| AU2019205330B2 (en) | 2018-01-04 | 2025-09-11 | Iconic Therapeutics Llc | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| TW202523847A (zh) | 2019-05-30 | 2025-06-16 | 美商磨石生物公司 | 經修飾之腺病毒 |
| US12280102B2 (en) | 2020-04-17 | 2025-04-22 | Vlp Therapeutics, Inc. | Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains |
| CN115552009A (zh) | 2020-04-30 | 2022-12-30 | Vlp治疗公司 | 细胞因子免疫疗法 |
| EP4192496A4 (en) | 2020-08-06 | 2025-01-01 | Gritstone bio, Inc. | MULTIEPITOP VACCINE CASSETTES |
| CN118510792A (zh) * | 2021-11-22 | 2024-08-16 | 诺瓦瓦克斯公司 | 用于治疗和预防疟疾的方法和组合物 |
| WO2025064770A2 (en) * | 2023-09-20 | 2025-03-27 | La Jolla Institute of Immunology | Alphavirus t cell epitopes, megapools and uses thereof |
| WO2025084276A1 (ja) * | 2023-10-16 | 2025-04-24 | Ｃｙｎ－Ｋバイオ株式会社 | 肥満の処置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100251505B1 (ko) * | 1991-11-16 | 2000-05-01 | 장 스테판느 | 말라리아원충으로부터의 cs 및 hbsag 사이의 혼성 단백질(hybrid protein between cs from plasmodium and hbsag) |
| AU2003295470A1 (en) | 2002-11-13 | 2004-06-03 | The United States Of America As Represented By The Secretary Of The Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
| US20080131461A1 (en) * | 2004-10-14 | 2008-06-05 | Crucell Holland B.V. | Malaria Prime/Boost Vaccines |
| GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| AU2007291936B2 (en) * | 2006-08-30 | 2012-09-27 | Artes Biotechnology Gmbh | Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
| CN102317308A (zh) * | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
| WO2011022002A1 (en) * | 2009-08-18 | 2011-02-24 | The Rockefeller University | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
| EP2477650B8 (en) * | 2009-09-18 | 2019-10-09 | FRAUNHOFER USA Inc. | Virus like particles comprising target proteins fused to plant viral coat proteins |
| WO2012006180A1 (en) * | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
| WO2012023995A1 (en) * | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
| US9487563B2 (en) * | 2011-01-31 | 2016-11-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles and methods of use |
| AU2013221187B9 (en) * | 2012-02-16 | 2018-01-04 | Vlp Therapeutics, Inc. | Virus like particle composition |
| WO2016021209A1 (en) | 2014-08-08 | 2016-02-11 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein e3 |
-
2014
- 2014-06-02 JP JP2015558676A patent/JP6734651B2/ja active Active
- 2014-06-02 MX MX2015016627A patent/MX386234B/es unknown
- 2014-06-02 SG SG10201709917VA patent/SG10201709917VA/en unknown
- 2014-06-02 AP AP2015008926A patent/AP2015008926A0/xx unknown
- 2014-06-02 KR KR1020217029655A patent/KR102494564B1/ko active Active
- 2014-06-02 EP EP14807026.1A patent/EP3004348B1/en active Active
- 2014-06-02 KR KR1020157035411A patent/KR20160016856A/ko not_active Ceased
- 2014-06-02 IL IL242656A patent/IL242656B/en unknown
- 2014-06-02 WO PCT/JP2014/065166 patent/WO2014196648A1/en not_active Ceased
- 2014-06-02 AU AU2014275772A patent/AU2014275772B2/en not_active Ceased
- 2014-06-02 RU RU2015155821A patent/RU2702163C2/ru active
- 2014-06-02 SG SG11201509614SA patent/SG11201509614SA/en unknown
- 2014-06-02 CA CA2913832A patent/CA2913832C/en active Active
- 2014-06-02 CN CN201480043750.5A patent/CN105431535A/zh active Pending
- 2014-06-02 BR BR112015030229-7A patent/BR112015030229B1/pt not_active IP Right Cessation
- 2014-06-03 TW TW103119188A patent/TWI687442B/zh active
- 2014-06-03 US US14/294,968 patent/US9512190B2/en active Active
-
2015
- 2015-11-24 ZA ZA2015/08642A patent/ZA201508642B/en unknown
-
2016
- 2016-10-21 US US15/299,859 patent/US20170035871A1/en not_active Abandoned
-
2019
- 2019-03-28 US US16/367,374 patent/US20190351041A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521539A5 (cg-RX-API-DMAC7.html) | ||
| JP2015508648A5 (cg-RX-API-DMAC7.html) | ||
| EP3177720B1 (en) | Virus like particle comprising modified envelope protein e3 | |
| RU2014133527A (ru) | Композиция вирусоподобных частиц | |
| US10464986B2 (en) | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen | |
| AU2014275772B2 (en) | Malaria vaccine | |
| US10385101B2 (en) | Virus like particle comprising modified envelope protein E3 | |
| KR20210074314A (ko) | 생체치료제의 투여를 위한 알파바이러스 기반 레플리콘 | |
| JP2016501535A5 (cg-RX-API-DMAC7.html) | ||
| WO2018176103A1 (en) | "chimeric molecules and uses thereof" | |
| JP2017513502A5 (cg-RX-API-DMAC7.html) | ||
| RU2017132190A (ru) | Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними | |
| CN102112601B (zh) | 新的融合蛋白及其用于制备针对丙型肝炎的疫苗的用途 | |
| CN107074968B (zh) | 疫苗 | |
| TH112180A (th) | โปรตีนผสมชนิดใหม่ ๆ และการใช้โปรตีนเหล่านี้เพื่อการเตรียมวัคซีนต้านไวรัสตับอักเสบ ซี | |
| Li JiaYi et al. | Immunogenicity of N-terminal 158 amino acid motif of E-protein of a newly purified mutant dengue virus from a Chinese patient. | |
| Honjo | New flavivirus antigens for production of vaccines against Japanese encep/ml~ pimmid vector mmtrucflon and gem in Esdm, iehia coil Res. Found. Microbial Dis. Osaka Univ. Belgium; 16 March 1987 | |
| TH159031A (th) | ไวรัสโรคหัดชนิดรีคอมบิแนนท์ที่แสดงออกถึงโพลิเพปไทด์ของไวรัสชิคุนกุนยา และการประยุกต์ใช้ |